Management of stable COPD

Patient Education and Counseling

Volumn 52, Issue 3, 2004, Pages 225-229

  Van Der Valk, Paul ^a   Monninkhof, Evelyn ^a   Van Der Palen, Job ^a   Zielhuis, Gerhard ^b   Van Herwaarden, Cees ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

COPD; Exacerbations; Health related quality of life; Optimisation of lung function; Self management; Self treatment of exacerbations; Smoking cessation; Treatment

Indexed keywords

ACETYLCYSTEINE; BRONCHODILATING AGENT; CORTICOSTEROID;

BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COPING BEHAVIOR; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DISEASE EXACERBATION; DRUG MEGADOSE; DYSPNEA; EXERCISE; HUMAN; LIFESTYLE; LONG TERM CARE; NUTRITION; OXYGEN THERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; SURVIVAL RATE;

EID: 1442333515     PISSN: 07383991     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-3991(03)00095-8     Document Type: Article

References (55)

1. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J. Respir. Crit. Care Med. 163:2001;1256-1276.
2. The World Health Report 1998. Geneva: World Health Organisation; 1998.
3. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 349:1997;1498-1504.
4. Morbidity & mortality: chartbook on cardiovascular, lung, and blood diseases. Bethesda (MD): National Heart, Lung and Blood Institute, Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998.
5. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1:1977;1645-1648.
6. Sandford A.J., Weir T.D., Pare P.D. Genetic risk factors for chronic obstructive pulmonary disease. Eur. Respir. J. 10:1997;1380-1391.
7. Schols A.M., Wouters E.F. Nutritional abnormalities and supplementation in chronic obstructive disease. Clin. Chest Med. 21:2002;753-762.
8. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A Statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159:S1-40.
9. Ferreira I., Brooks D., Lacasse Y., Goldstein R. Nutritional intervention in COPD: a systematic overview. Chest. 119:2001;353-363.
10. Yusen R. What outcomes should be measured in patients with COPD? Chest. 119:2001;327-328.
11. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 117:2000;398S-401S.
12. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. 157:1998;1418-1422.
13. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S.et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA. 272:1994;1497-1505.
14. Barnes P.J. New therapies for chronic obstructive pulmonary disease. Thorax. 53:1998;137-147.
15. Scanlon P.D., Connett J.E., Waller L.A., Altose M.D., Bailey W.C., Sonia B.A. Lung health study research group DP. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study. Am J. Respir. Crit. Care Med. 161:2000;381-390.
16. Wilson D., Parsons J., Wakefield M. The health-related quality-of-life of never smokers, ex-smokers, and light, moderate, and heavy smokers. Prev. Med. 29:1999;139-144.
17. Fiore M, Bailey, W, Bennett, G, Cohen, S, Dorfman, SF, Fox, B, et al. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville (MD): US Department of Health and Human Services. Public Health Service; 2000.
18. Pieterse M.E., Seydel E.R., DeVries H. Diffusion of a minimal contact smoking cessation program for Dutch general practitioners. Psycho-Oncol. 5:1996;186. [abstract].
19. Tashkin D.P., Kanner R., Bailey W., Buist S., Anderson P., Nides M.A.et al. Smoking cessation in patients witch chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 357:2001;1571-1575.
20. Celli, BR. Clinical management of COPD. In: Voelkel, NF, MacNee, W, editors. London: Chronic Obstructive Lung Disease BC Decker Inc.; 2002. p. 319-31.
21. Barnes P.J. Chronic obstructive pulmonary disease. N Engl. J. Med. 343:2000;269-280.
22. Calverley P.M. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. 161:2000;341-342.
23. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-4.
24. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
25. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. 320:2000;1297-1303.
26. Paggiaro P.L., Dahle R., Bakran I., Frith L., Hollingworth K., Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD study group. Lancet. 351:1998;773-780.
27. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Int. Med. 159:1999;941-955.
28. Stey C., Steurer J., Bachmann S., Medici T.C., Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 16:2000;253-262.
29. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 22:2000;209-221.
30. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Int Med 1980;93:391-8.
31. American Thoracic Society. Pulmonary rehabilitation-1999. Am J Respir Crit Care Med 19991;59:1666-82.
32. Cox N.J., Hendricks J.C., Binkhorst R.A., Van Herwaarden C.L.A. A pulmonary rehabilitation program for patients with asthma and mild chronic obstructive pulmonary diseases (COPD). Lung. 171:1993;235-244.
33. Wijkstra P.J., Ten Vergert E.M., Van Altena R., Otten V., Kraan J., Postma D.S.et al. Long term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax. 50:1995;824-828.
34. Strijbos J.H., Postma D.S., Van Altena R., Gimeno F., Koëter G.H. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest. 109:1996;366-372.
35. Hernandez M.T., Rubio T.M., Ruiz F.O., Riera H.S., Gil R.S., Gomez J.C. Results of a home-based training program for patients with COPD. Chest. 118:2000;106-114.
36. Reardon J.Z., Awad E., Normandin E., Vale F., Clark B., ZuWallack R.L. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest. 105:1994;1046-1052.
37. Ries A.L., Kaplan R.M., Limberg T.M., Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Int. Med. 122:1995;823-832.
38. Ojanen M., Lahdensuo A., Laitinen J., Karvonen J. Psychosocial changes in patients participating in a chronic obstructive pulmonary disease rehabilitation program. Respiration. 60:1993;96-102.
39. Couser J.I. Jr., Guthmann R., Hamadeh M.A., Kane C.S. Pulmonary rehabilitation improves exercise capacity in older elderly patients with COPD. Chest. 107:1995;730-734.
40. Goldstein R.S., Gort E.H., Stubbing D.G., Avendano M.A., Guyatt G.H. Randomised controlled trial of respiratory rehabilitation. Lancet. 344:1994;1394-1397.
41. Wijkstra P.J., Van Altena R., Kraan J., Otten V., Postma D.S., Koëter G.H. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur. Respir. J. 7:1994;269-273.
42. Engelen M.P., Schols A.M., Baken W.C., Wesseling G.J., Wouters E.F. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur. Respir. J. 7:1994;1793-1797.
43. Schols A.M., Soeters P.B., Dingemans A.M., Mostert R., Frantzen P.J., Wouters E.F. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev. Respir. Dis. 147:1993;1151-1156.
44. Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. 157:1998;1791-1797.
45. Schols A. Nutritional depletion and physical impairment in patients with chronic obstructive pulmonary disease. Implications for therapy, University of Maastricht; 1992. p. 58-9.
46. Gallefoss F., Bakke P.S., Rsgaard P.K. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. 159:1999;812-817.
47. Van der Waart M.A.C., Dekker F.W., Nijhof S. NHG-standaard CARA bij volwassenen: behandeling (Dutch standard by National GP Association for CARA in adults). Huisarts Wet. 35:1992;437-443.
48. Gibson, PG, Coughlan, J, Wilson, AJ, Hensley, MJ, Abramson, M, Bauman, A, Walters, EH. Limited (information only) Patient Education Programs for Adults with Asthma (Cochrane Review), issue 1. Oxford: The Cochrane Library; 2000.
49. Clark N.M. Asthma self-management education research and implications for clinical practice. Chest. 95:1989;1110-1113.
50. Pieterse GC, Taal E, Seydel, ER. Psychosociale aspecten van CARA: Ziektelast en interventiestrategiën voor patiëntenvoorlichting (Social aspect of CARA). Enschede: Universiteit Twente; 1992.
51. Gallefoss F., Bakke P.S. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J. Respir. Crit. Care Med. 160:1999;2000-2005.
52. Gibson PG, Coughlan J, Wilson, AJ, Abramson M, Bauman A, Hensley, MJ, Walters, EH. Self-Management Education and Regular Practitioner Review for Adults with Asthma (Cochrane Review), issue 1. The Cochrane Library; 2000.
53. Klein J.J., van der P.J., Uil S.M., Zielhuis G.A., Seydel E.R., van Herwaarden C.L. Benefit from the inclusion of self-treatment guidelines to a self-management programme for adults with asthma. Eur. Respir. J. 17:2001;386-394.
54. Lahdensuo A., Haahtela T., Herrala J., Kava T., Kiviranta K., Kuusisto P.et al. Randomised comparison of guided self management and traditional treatment of asthma over 1 year. Br. Med. J. 312:1996;748-752.
55. Monninkhof, EM, Van der Valk, PDLPM., Van der Palen J, Van Herwaarden CLA, Partridge, MR, Walters, EH., Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library; 2002.